Ian L. Scott, Ph.D.
Head of Chemistry and Biology - Acting Head of Toxicology and ADME - Executive leadership of research and non-clinical development - Management of Acucela's patent portfolio and IP strategies Member of Joint Development Committee for external collaboration with Otsuka Pharmaceuticals - Facilities management
The Visual Cycle Modulators
Dr. Ian L. Scott:
ACU-4429 Research Program Leader:
Acucela Inc. 2005 - 2010
Acucela Inc. is a biotechnology company dedicated to the discovery of small-molecule therapeutics for the treatment of blinding eye diseases. Dr. Scott began his work with Acucela as the Director of Chemistry in 2005, and proceeded to become the principle inventor of Emixustat HCl, (ACU-4429). By 2008, Dr. Scott was formally recognized for his scientific and leadership achievments, and promoted to Senior Director of Chemistry and Biology. In this role, he was responsible for all non-clinical research and development. In 2009, Dr. Scott was further recognized for his outstanding work and presented with The Dr. Kubota Award.
Principal inventor of Emixustat HCl (ACU-4429), currently in Phase IIb/III trials for AMD
Discovery of 6 novel, related chemical classes
Authorship of 6 patent applications
The Visual Cycle Modulator (VCM) program involves the invention and development of ACU-4429, a small molecule inhibitor of RPE65 isomerase for the treatment of Age-Related Macular Degeneration (AMD).
Chemelian, Inc. is a virtual company working to develop Allosteric Intelligence (TM), a new, ultra-fast and efficient approach to drug discovery. Fragment-based drug design is uniquely integrated with classical medicinal chemistry, NMR, and allosteric modulators to maximize the strengths of each, and bypass well-known weaknesses. Allosteric Intelligence gives Chemelian an unsurpassed ability to discover novel therapies. Dr. Ian Scott is the President and Founder of Chemelian, Inc.
Spectrum Pharmaceuticals 2011 - 2014
Spectrum Pharmaceuticals is a mid-size company focused on the development of drugs to treat cancer. Spectrum's product portfolio includes small molecules, biologics and inorganics: 2 marketed products, 2 products in late stage development and 8 products in Phase 1, 2. Spectrum exercises global resources by outsourcing all development activities to the most qualified CROs and CMOs worldwide. Dr. Scott directed all of Spectrum's chemical develpment. His work includes preparation and review of section 3.2.S for multiple NDA filings.
Allergan is a global, technology-driven multi-specialty health care company focused in the areas of eye care, neurosciences, medical dermatology and urology.
Dr. Scott was responsible for all stages of API manufacture, from new route discovery through process optimization and GMP manufacture; management of chemistry outsourcing relationships (EU, North America, India); integration of process and medicinal chemistry programs.